NYSEAMERICAN:CCEL Cryo-Cell International (CCEL) Stock Price, News & Analysis $3.68 +0.18 (+5.14%) Closing price 04:10 PM EasternExtended Trading$3.69 +0.01 (+0.24%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Cryo-Cell International Stock (NYSEAMERICAN:CCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CCEL alerts:Sign Up Key Stats Today's Range$3.42▼$3.7850-Day Range$2.89▼$4.0852-Week Range$2.72▼$6.35Volume20,952 shsAverage Volume13,933 shsMarket Capitalization$29.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Cryo-Cell International, Inc. is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods. The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth. Trained medical personnel coordinate with healthcare providers to collect cord blood and cord tissue immediately after delivery. Samples are shipped in temperature-controlled containers to Cryo-Cell’s processing laboratories, where stem cell fractions are isolated, tested for purity and viability, and ultimately cryogenically stored in liquid nitrogen tanks. Cryo-Cell serves families across the United States and in select international markets through a network of distribution partners. In addition to its core storage offerings, the company provides customized preservation plans, educational materials and dedicated client support to prospective parents. Cryo-Cell also collaborates with research institutions and participates in industry initiatives aimed at expanding the therapeutic applications of cord blood and tissue derivatives. Guided by an experienced management team with expertise in biotechnology, clinical operations and regulatory affairs, Cryo-Cell International continues to invest in advanced processing technologies and service expansion. The company’s focus on safety, compliance and customer engagement positions it as a leading player in the evolving field of regenerative medicine and stem cell banking.AI Generated. May Contain Errors. Read More Cryo-Cell International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreCCEL MarketRank™: Cryo-Cell International scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingCryo-Cell International has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCryo-Cell International has received no research coverage in the past 90 days.Read more about Cryo-Cell International's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cryo-Cell International is -10.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cryo-Cell International is -10.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.14% of the float of Cryo-Cell International has been sold short.Short Interest Ratio / Days to CoverCryo-Cell International has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cryo-Cell International has recently decreased by 11.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCryo-Cell International does not currently pay a dividend.Dividend GrowthCryo-Cell International does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentCryo-Cell International has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cryo-Cell International this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cryo-Cell International insiders have not sold or bought any company stock.Percentage Held by Insiders38.59% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions10.44% of the stock of Cryo-Cell International is held by institutions.Read more about Cryo-Cell International's insider trading history. Receive CCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CCEL Stock News HeadlinesCryo-Cell Receives Acceptance of Compliance Plan From NYSE AmericanMay 8, 2026 | businesswire.comCryo-Cell International (NYSEAMERICAN:CCEL) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedMay 8, 2026 | americanbankingnews.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 14 at 1:00 AM | Brownstone Research (Ad)Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood BanksApril 28, 2026 | finance.yahoo.comWall Street Analysts Are Neutral on Top Healthcare PicksApril 19, 2026 | theglobeandmail.comCryo-Cell International receives NYSE American notice over listing non-complianceMarch 13, 2026 | msn.comCryo-Cell Receives NYSE American Continued Listing NoticeMarch 12, 2026 | businesswire.comCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025February 27, 2026 | businesswire.comSee More Headlines CCEL Stock Analysis - Frequently Asked Questions How have CCEL shares performed this year? Cryo-Cell International's stock was trading at $3.44 on January 1st, 2026. Since then, CCEL stock has increased by 7.0% and is now trading at $3.68. How were Cryo-Cell International's earnings last quarter? Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) issued its quarterly earnings data on Tuesday, April, 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business earned $7.68 million during the quarter. How do I buy shares of Cryo-Cell International? Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cryo-Cell International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Crescent Biopharma (CBIO), NVIDIA (NVDA), Aspen Group (ASPU). Company Calendar Last Earnings4/14/2026Today5/14/2026Fiscal Year End11/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CCEL's financial health is in the Red zone, according to TradeSmith. CCEL has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNYSEAMERICAN:CCEL CIK862692 Webwww.cryo-cell.com Phone(813) 749-2100Fax813-855-4745Employees90Year Founded1989Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.43 million Net Margins-8.52% Pretax Margin-8.95% Return on EquityN/A Return on Assets-4.26% Debt Debt-to-Equity RatioN/A Current Ratio0.62 Quick Ratio0.60 Sales & Book Value Annual Sales$31.57 million Price / Sales0.94 Cash FlowN/A Price / Cash FlowN/A Book Value($2.31) per share Price / Book-1.59Miscellaneous Outstanding Shares8,060,000Free Float4,947,000Market Cap$29.66 million OptionableNot Optionable Beta0.49 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSEAMERICAN:CCEL) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cryo-Cell International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cryo-Cell International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.